Kalshi Expands Into Drug Trial and FDA Bets, Eyes Flight-Delay Contracts
Updated
Updated · The Guardian · Jul 16
Kalshi Expands Into Drug Trial and FDA Bets, Eyes Flight-Delay Contracts
3 articles · Updated · The Guardian · Jul 16
Summary
Kalshi said its new biopharma pilot will let users trade contracts on clinical trial results and FDA decisions, widening the prediction platform beyond politics and sports.
AppliedXL is partnering on the launch, which Kalshi says could create a continuously updated public probability for drug outcomes in an industry where key data often stays hidden.
Employment verification and post-enrollment listing rules are meant to curb insider trading and avoid disrupting recruitment, after recent scrutiny of prediction-market bets tied to political events.
A separate CFTC filing covers airport flight-cancellation contracts based on FlightAware data, though Kalshi said that market is still under evaluation and not yet live.
Kalshi’s push comes as the platform reports $1 billion in trading volume on this year’s Super Bowl Sunday and more than 5 million monthly users, even as critics warn of manipulation and addiction risks.
As betting on drug trials grows, where is the line between market insight and gambling on human health?
Facing a potential ban on its core business, is Kalshi's biopharma expansion a brilliant pivot or a desperate gamble?
In the race to predict drug success, will the wisdom of the crowd be outsmarted by artificial intelligence?
Kalshi and AppliedXL Launch $24B Clinical Trial Prediction Markets: AI, Ethics, and the Future of Biotech Betting
Overview
In July 2026, Kalshi and AppliedXL launched new prediction markets for betting on biotech clinical trials and drug approvals, aiming to bring transparency to a sector where the odds of drug success are usually hidden and information is often incomplete. Developing a drug is extremely costly, and companies’ futures can depend on a single trial, yet most success estimates remain confidential. Kalshi’s markets address this information gap by creating a real-time, public consensus on drug prospects. AppliedXL’s AI-driven prediction system adds nuance by analyzing trial outcomes beyond simple success or failure, offering more detailed and relevant forecasts for investors and the public.